Effects of Arsenic in Drinking Water on Risk of Hepatitis or Cirrhosis in Persons With and Without Chronic Viral Hepatitis
- PMID: 27060428
- DOI: 10.1016/j.cgh.2016.03.043
Effects of Arsenic in Drinking Water on Risk of Hepatitis or Cirrhosis in Persons With and Without Chronic Viral Hepatitis
Abstract
Background & aims: Arsenic in drinking water is associated with hepatomegaly and death from liver cancer. However, confounding factors related to liver diseases have not been carefully studied. We examined associations between exposure of arsenic in drinking water and risk of hepatitis and cirrhosis, and the interaction with chronic viral hepatitis, in people living in the Lanyang Basin of northeastern Taiwan, where well water has an arsenic content that ranges from undetectable to 3590 μg/L.
Methods: We tested blood samples from 4387 people who lived in arseniasis-endemic areas in northeastern Taiwan from 1991 through 1994 for hepatitis B virus DNA, hepatitis B surface antigen (HBsAg), and antibodies against hepatitis C virus (anti-HCV). We measured arsenic concentrations in well water and collected information on residents' histories of major chronic diseases. Reports of chronic hepatitis or cirrhosis were ascertained using the Taiwan National Health Insurance database. Reports of liver cancer were ascertained using the Taiwan National Cancer Registry.
Results: Prevalence odds ratios in the overall study population for chronic hepatitis or cirrhosis for well water arsenic concentrations of ≤10 μg/L were 1.00 (reference), 0.93 for 10.1-49.9 μg/L (95% confidence interval [CI], 0.57-1.52), 1.24 for 50.0-99.9 μg/L (95% CI, 0.68-2.23), 0.98 for 100.0-299.9 (95% CI, 0.52-1.85), and 1.86 for ≥300.0 μg/L (95% CI, 1.08-3.20). Increasing levels of arsenic in drinking water were associated with increasing prevalence of chronic hepatitis or cirrhosis in residents who were seronegative for HBsAg and seronegative for anti-HCV, but not for seropositive for either HBsAg or anti-HCV. In individuals who were seropositive for HBsAg or anti-HCV, we observed an inverse association between hepatitis or cirrhosis and consumption of water with levels of arsenic ≥100.0 μg/L. Among participants who were seropositive for HBsAg or anti-HCV, consumption of water with levels of arsenic ≥100.0 μg/L was associated with a reduced risk of liver cancer (multivariate-adjusted hazard ratio, 0.29; 95% CI, 0.09-0.95; P < .05). A higher proportion of individuals exposed to cumulative arsenic level >14,000 μg/L ×year were carriers of inactive hepatitis B virus (DNA <10,000 copies/mL) and were positive for HBsAg (60%) than individuals exposed to water below this arsenic level (35%).
Conclusions: Concentrations of arsenic concentration in drinking water ≥300.0 μg/L significantly increase risk of hepatitis or cirrhosis in people without chronic viral hepatitis. However, in people with chronic viral hepatitis, levels of arsenic ≥100.0 μg/L in drinking water significantly reduce the risk of chronic hepatitis or cirrhosis.
Keywords: Carcinogen; Contamination; Environmental Factors; Pollution.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Natural history of chronic hepatitis B REVEALed.J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. J Gastroenterol Hepatol. 2011. PMID: 21323729 Review.
-
Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.Clin Gastroenterol Hepatol. 2016 Mar;14(3):461-468.e2. doi: 10.1016/j.cgh.2015.10.033. Epub 2015 Nov 18. Clin Gastroenterol Hepatol. 2016. PMID: 26598229
-
Smoking and alanine aminotransferase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression.Arch Intern Med. 2002 Apr 8;162(7):811-5. doi: 10.1001/archinte.162.7.811. Arch Intern Med. 2002. PMID: 11926856
-
Arsenic Exposure From Drinking Water and the Incidence of CKD in Low to Moderate Exposed Areas of Taiwan: A 14-Year Prospective Study.Am J Kidney Dis. 2017 Dec;70(6):787-797. doi: 10.1053/j.ajkd.2017.06.012. Epub 2017 Aug 23. Am J Kidney Dis. 2017. PMID: 28844585
-
What can we learn from hepatitis B virus clinical cohorts?Liver Int. 2015 Jan;35 Suppl 1:91-9. doi: 10.1111/liv.12716. Liver Int. 2015. PMID: 25529093 Review.
Cited by
-
GT-Repeat Polymorphism in the HO-1 Gene Promoter Is Associated with Risk of Liver Cancer: A Follow-Up Study from Arseniasis-Endemic Areas in Taiwan.J Clin Med. 2021 Apr 3;10(7):1489. doi: 10.3390/jcm10071489. J Clin Med. 2021. PMID: 33916685 Free PMC article.
-
Resveratrol Alleviates Arsenic Exposure-Induced Liver Fibrosis in Rats by Inhibiting Hepatocyte Senescence.Biol Trace Elem Res. 2025 Mar;203(3):1528-1538. doi: 10.1007/s12011-024-04255-9. Epub 2024 Jun 3. Biol Trace Elem Res. 2025. PMID: 38831176
-
Carcinogenic effect of arsenic in digestive cancers: a systematic review.Environ Health. 2023 Apr 17;22(1):36. doi: 10.1186/s12940-023-00988-7. Environ Health. 2023. PMID: 37069631 Free PMC article.
-
Inhibition of Histone H3K18 Acetylation-Dependent Antioxidant Pathways Involved in Arsenic-Induced Liver Injury in Rats and the Protective Effect of Rosa roxburghii Tratt Juice.Toxics. 2023 Jun 3;11(6):503. doi: 10.3390/toxics11060503. Toxics. 2023. PMID: 37368603 Free PMC article.
-
Arsenic trioxide impacts hepatitis B virus core nuclear localization and efficiently interferes with HBV infection.Microbiol Spectr. 2024 May 2;12(5):e0378823. doi: 10.1128/spectrum.03788-23. Epub 2024 Apr 3. Microbiol Spectr. 2024. PMID: 38567974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical